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pig model of LPS-induced pulmonary
inflammation: II. Effects on skeletal muscle
atrophy
Koen JP Verhees1, Nicholas AM Pansters1, Hoeke A Baarsma2,3, Alexander HV Remels1, Astrid Haegens1,
Chiel C de Theije1, Annemie MWJ Schols1, Reinoud Gosens2,3 and Ramon CJ Langen1*Abstract
Background: Chronic obstructive pulmonary disease (COPD) is accompanied by pulmonary inflammation and
associated with extra-pulmonary manifestations, including skeletal muscle atrophy. Glycogen synthase kinase-3
(GSK-3) has been implicated in the regulation of muscle protein- and myonuclear turnover; two crucial processes
that determine muscle mass. In the present study we investigated the effect of the selective GSK-3 inhibitor
SB216763 on muscle mass in a guinea pig model of lipopolysaccharide (LPS)-induced pulmonary inflammation-
associated muscle atrophy.
Methods: Guinea pigs were pretreated with either intranasally instilled SB216763 or corresponding vehicle prior to
each LPS/saline challenge twice weekly. Pulmonary inflammation was confirmed and indices of muscle mass were
determined after 12 weeks. Additionally, cultured skeletal muscle cells were incubated with tumor necrosis factor α
(TNF-α) or glucocorticoids (GCs) to model the systemic effects of pulmonary inflammation on myogenesis, in the
presence or absence of GSK-3 inhibitors.
Results: Repeated LPS instillation induced muscle atrophy based on muscle weight and muscle fiber cross
sectional area. Intriguingly, GSK-3 inhibition using SB216763 prevented the LPS-induced muscle mass decreases and
myofiber atrophy. Indices of protein turnover signaling were unaltered in guinea pig muscle. Interestingly, inhibition
of myogenesis of cultured muscle cells by TNF-α or synthetic GCs was prevented by GSK-3 inhibitors.
Conclusions: In a guinea pig model of LPS-induced pulmonary inflammation, GSK-3 inhibition prevents skeletal
muscle atrophy without affecting pulmonary inflammation. Resistance to inflammation- or GC-induced impairment
of myogenic differentiation, imposed by GSK-3 inhibition, suggests that sustained myogenesis may contribute to
muscle mass maintenance despite persistent pulmonary inflammation. Collectively, these results warrant further ex-
ploration of GSK-3 as a potential novel drug target to prevent or reverse muscle wasting in COPD.
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Chronic obstructive pulmonary disease (COPD) is charac-
terized by an irreversible and persistent airflow limitation
and is associated with pulmonary inflammation [1-3].
COPD is also typified by significant extra-pulmonary
manifestations, that contribute to increased morbidity and
mortality, independent of the primary pathology [4]. Inter-
estingly, pulmonary inflammation has been suggested as a
trigger and perpetuating factor in the local and systemic
pathology of COPD. One of the major systemic conse-
quences of COPD is peripheral muscle dysfunction,
comprising a loss of muscle strength and endurance,
respectively [5-7]. A major cause of loss of muscle
strength is the decrease in muscle mass due to myofiber
atrophy [8-11].
Skeletal muscle atrophy or muscle wasting may be the
consequence of a disturbed balance between protein
synthesis and degradation in favor of the latter; due to
either accelerated breakdown of muscle proteins, or re-
duced protein synthesis [9,12,13]. Insulin-like growth
factor I (IGF-I) and insulin are both anabolic factors that
affect cellular protein turnover via a well-characterized
signaling conduit that includes phosphorylation of
phosphatidylinositol-3 kinase (PI-3K), resulting in the
activation of Akt/PKB (hereafter termed Akt) [13].
Phosphorylated Akt can, in turn, stimulate protein syn-
thesis by activating mammalian target of rapamycin
(mTOR) signaling, characterized by phosphorylation of
its downstream substrates 4E-BP1 and p70S6K [13].
Conversely, Akt activation results in the phosphoryl-
ation and subsequent cytoplasmic retention of the
Forkhead box O (FoXO) class of transcription factors,
which have been implicated in the coordination of pro-
teolytic gene expression [14-16].
In addition to protein turnover, myonuclear turnover,
i.e. the balance between myonuclear loss and myonuclear
accretion, may constitute an additional cellular mechan-
ism determining muscle mass [17]. Efficient regeneration
and restoration of muscle mass following injury or recov-
ery from atrophy requires activation, proliferation and
subsequent differentiation of satellite cells into myoblasts
that fuse with existing or form new myofibers [18,19].
Besides myoblast fusion, myogenic differentiation is char-
acterized by increased transcriptional activity of muscle
regulatory factors (MRFs) (e.g. MyoD, myogenin), which
promote the expression of muscle-specific genes, includ-
ing contractile/sarcomeric proteins such as troponin-I
(TnI), myosin light chain (MyLC) and myosin heavy chain
(MyHC), and enzymes involved in muscle energy metab-
olism (e.g. muscle creatine kinase (MCK)) [20].
Besides the pulmonary pathology, systemic inflammation
in COPD, which manifests itself as increased activation of
circulating inflammatory cells and elevated levels of TNF-α
or IL-1β, as well as increased serum concentrations ofacute phase proteins such as C-reactive protein (CRP)
[21-23], may directly or indirectly contribute to skeletal
muscle atrophy [24,25]. In a mouse model of pulmonary
inflammation, we recently demonstrated that muscle
NF-κB activation was required for the transition from
inflammatory- to muscle atrophy signaling [26], sug-
gesting that systemic inflammation contributes to the
loss of skeletal muscle mass following acute pulmonary
inflammation. Furthermore, the release of glucocorti-
coids (GCs) as an endogenous response to inflamma-
tion, or the administration of synthetic GCs to COPD
patients as a common intervention during acute exacer-
bations or end stage disease may also evoke or aggravate
muscle wasting as GCs are potent inducers of muscle
atrophy [27-30].
Currently, pharmacological treatment approaches of
muscle atrophy in COPD are limited [31-33], and thera-
peutic interventions should be aimed at suppression of
triggers of muscle atrophy, e.g. pulmonary inflammation,
or at direct modulation of the signaling pathways that
regulate muscle mass. Glycogen synthase kinase-3 (GSK-3)
is a ubiquitously expressed serine/threonine kinase, occur-
ring in two closely related isoforms, namely GSK-3α and
GSK-3β, which share extensive homology in their kinase
domains [34-36]. GSK-3β is a signaling protein directly
downstream of Akt, which plays an important role in a
myriad of cellular processes, including inflammatory sig-
naling [37,38] and protein synthesis [39], through regula-
tion of mRNA translation initiation via suppression of
eIF2B activity. Recent data from our group and others sug-
gests a pivotal role for GSK-3β in the determination of
muscle mass, as it is involved in both protein and myonuc-
lear turnover. Concretely, it was established that muscle
atrophy, resulting from increased proteolysis signaling fol-
lowing synthetic GC-treatment, requires GSK-3β [40]. In
another study by our group physiological and pharmaco-
logical GSK-3 inhibition enhanced myoblast fusion and
myotube formation, in support of an important role of
GSK-3 in the regulation of myonuclear turnover [41].
Considering the significance of GSK-3 in the cellular
processes controlling inflammatory signaling and muscle
mass, the purpose of this study was to assess the potential
therapeutic effects of GSK-3 enzyme inhibition on muscle
wasting in an established guinea pig model of lipopolysac-
charide (LPS)-induced pulmonary inflammation, using the
selective inhibitor 3-(2,4-dichlorophenyl)-4-(1-methyl-1H-
indol-3-yl)-1H-pyrrole-2,5-dione (SB216763) [42]. The data
presented in this study demonstrate that topical application
of a GSK-3 inhibitor does not affect pulmonary inflamma-
tion, but reduces skeletal muscle atrophy. Subsequent cell
culture experiments suggested this may involve mainten-
ance of myogenesis, as GSK-3 inhibition restored muscle
differentiation in the presence of effectors of systemic
inflammation. Collectively, these current findings warrant
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Methods
Animals
Outbred, male, specified pathogen-free Dunkin Hartley
guinea pigs (Harlan, Heathfield, UK) were used in this
study. All protocols described in this manuscript were
approved by the University of Groningen Committee for
Animal Experimentation.
Experimental protocol
Thirty-six guinea pigs, 12 ± 4 wks of age were randomly
assigned to four experimental groups (n = 9), namely: (1)
vehicle-treated, saline-challenged; (2) SB216763-treated
saline-challenged; (3) vehicle-treated, LPS-challenged, and
(4) SB216763-treated, LPS-challenged. The guinea pigs
were treated twice per week for 12 consecutive weeks by
intranasal instillation of 100 μl SB216763 (sterile, 2 mM in
10% (v/v) DMSO in saline) or vehicle (100 μl 10% (v/v)
DMSO in sterile saline). After the intranasally instilled so-
lution was aspirated, the animals were kept in an upright
position for an additional 2 min, to allow sufficient
spreading of the fluid throughout the lungs. The animals
were intranasally instilled with 100 μl LPS (10 mg/ml in
sterile saline) or sterile saline, 30 min post SB216763 or
vehicle instillation. SB216763 is a selective GSK-3 inhi-
bitor (3-(2,4-dichlorophenyl)-4-(1-methyl-1H-indol-3-yl)-
1H-pyrrole-2,5-dione) (Tocris Cookson, Bristol, UK) and
the LPS was derived from Escherichia coli, serotype 055:
B5 (Sigma-Aldrich, MO, USA). Twenty-four hours after
the last instillation, the guinea pigs were sacrificed by ex-
perimental concussion, followed by rapid exsanguination.
Next, the lungs and a series of hind limb muscles in-
cluding the M. gastrocnemius, M. tibialis anterior, M.
plantaris and M. extensor digitorum longus (EDL) were
collected using standardized dissection methods. Inde-
pendent muscle weights of a single hind limb were mea-
sured and all tissues were immediately flash-frozen in
liquid nitrogen.
Tissue processing and histological analyses
The EDL muscles were embedded in Tissue-Tek (Sakura
Finetek, the Netherlands) and sectioned on a Leica
CM3050 S cryostat at −20°C. Subsequently, serial cross-
sections (5 μm) were stained with the following primary
antibodies: anti-Type I MyHC (#A4840) (Developmental
Studies Hybridoma Bank, Iowa City, IA, USA), and anti-
laminin (#L-9393) (Sigma-Aldrich) to determine the fiber
cross-sectional area (CSA) and fiber type distribution. The
sections were incubated with the following secondary anti-
bodies: goat anti-mouse IgM Alexa Fluor 555 (#A-21426)
and goat anti-rabbit IgG Alexa Fluor 350 (#A-11069)
(both from Invitrogen, CA, USA). Digital images of thestained sections were taken under 200X total magnifica-
tion using an Eclipse E800 microscope (Nikon, Japan)
connected to a digital camera (DXM, 1200 NF, Nikon,
Japan). The CSA was measured after having identified five
non-overlapping regions containing a total of 100–200 in-
dividual fibers per animal, which were then analyzed using
Lucia Software (version 4.81).
Cell culture
The murine skeletal muscle cell line C2C12 (ATCC #
CRL1772) was cultured in growth medium (GM), com-
posed of low glucose (1 g/l) Dulbecco’s Modified Eagle
Medium (DMEM) containing antibiotics (50 U/ml Peni-
cillin and 50 μg/ml Streptomycin) and 9% (v/v) Fetal
Bovine Serum (FBS) (all from Gibco, MD, USA). The
C2C12 cells were plated overnight in GM at 10
4/cm2 on
BD Matrigel coated (1:50 in DMEM low glucose) 35 mm
dishes as described previously (both from BD Biosciences,
MA, USA) [43]. To study effects on myogenesis, differen-
tiation was induced by growth factor withdrawal [44], re-
placing GM with differentiation medium (DM) (DMEM,
low glucose, with 1% heat-inactivated FBS and antibiotics).
The synthetic GC dexamethasone (hereinafter referred to
as Dex) (Sigma-Aldrich), TNF-α (Calbiochem, CA, USA),
with or without LiCl (Sigma-Aldrich) or CHIR99021
(2 μM) (kindly provided by Dr. Cohen, MRC Protein
Phosphorylation Unit, University of Dundee, UK) were
directly added to the culture medium upon the induction
of differentiation and again 24 h later when the cells were
provided with fresh DM. The myocytes were allowed to
differentiate for a total of 72 h, in absence or presence of
Dex (10 μM) or TNF-α (1 ng/ml) prior to analysis of myo-
genesis markers.
Myogenic index
As a morphological parameter of myogenesis, the myo-
genic index was determined to quantitate myoblast fu-
sion. The C2C12 cells were induced to differentiate for
72 h either in the presence or absence of Dex or TNF-α.
After 72 h of differentiation the cells were washed twice
in 1× PBS (RT), subsequently fixed in methanol and
stained in May-Grünwald Giemsa (Sigma-Aldrich) ac-
cording to the manufacturer’s instructions. Pictures were
taken at 40× and 100× magnifications using an inverted
light microscope (Eclipse E800, Nikon, Japan) connected
to a digital camera (DXM, 1200 NF, Nikon, Japan). The
100× magnified images were taken in series of four with
a fixed overlap. The total number of nuclei in 4 or more
fields was counted, and nuclei were assigned to one of
three classes: (1) single nucleated myoblasts; (2) divid-
ing or fusing bi-nucleated myoblasts, and (3) multi-
nucleated (> 2 nuclei) myotubes. Per condition, 1900 or
more nuclei were counted and assigned to either of the
above-mentioned classes.
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Measurements of Troponin I (TnI) promoter activity
during differentiation were performed by creating a stable
C2C12 cell line carrying a genomic TnI promoter-luciferase
reporter gene as described previously [45]. To determine
the luciferase activity, the cells were washed twice in ice-
cold 1× PBS, lysed in 1× reporter lysis buffer (Promega,
Madison, WI, USA) and stored at −80°C. The lysates were
spun at 14000 rpm (4°C) prior to analysis, and the soluble
fraction was used to measure the luciferase activity accord-
ing to the manufacturer’s instructions (Promega). The total
protein concentration was assessed using a Bio-Rad protein
assay kit (Bio-Rad, CA, USA) according to the manufac-
turer’s instructions. The data was corrected for total pro-
tein content.
Muscle creatine kinase activity
Myogenic differentiation was assessed biochemically by
measuring muscle creatine kinase (MCK) activity. After
the induction of differentiation, the C2C12 cells were
washed twice in ice-cold 1× PBS, subsequently lysed in
0.5% Triton X-100, and scraped from the dish with a cell
scraper (rubber policeman). The lysates were centrifuged
for 2 min at 14000 rpm (4°C), and the supernatant was
aliquoted and stored at −80°C to determine the protein
content or MCK activity in the presence of 1.25% BSA.
The MCK-activity was measured spectrophotometric-
ally (Stanbio Laboratory, TX, USA) [46]. The specific
activity was calculated after correction for total protein
content [47].
Western blotting
The muscle tissue was homogenized in ice-cold 1X whole
cell lysate buffer (WCL) (50 mM Tris–HCl, pH 7.4;
150 mM NaCl; 1 mM EDTA; 1 mM Na3VO4; 5 mM NaF;
10% glycerol; 0.5% Nonidet P-40; 1 mM DTT; 1 mM
PMSF; 10 μg/ml leupeptin; 1% aprotinin; 10 mM β-
glycerophosphate and 1 mM Na-pyro-PO4) using a ro-
tating blade tissue homogenizer (Polytron PT 1600E,
Kinematica, Switzerland). The C2C12 cells were washed
twice in ice-cold 1× PBS after which they were lysed in
1× reporter lysis buffer and scraped of the dish using
cell scrapers. The total protein concentration was assessed
by the Thermo Scientific Pierce BCA Protein Assay kit
(Pierce Biotechnology, IL, USA) according to the manu-
facturer’s instructions. The protein lysates were boiled for
5 min at 95°C after addition of 4× Laemmli sample buffer
(0.25 M Tris–HCl pH 6.8; 8% (w/v) SDS; 40% (v/v) gly-
cerol; 0.4 M DTT and 0.04% (w/v) Bromophenol Blue).
For SDS-PAGE 1–25 μg of protein was loaded per lane
and separated on a Criterion XT Precast 4 - 12% Bis-Tris
gel (Bio-Rad), followed by transfer to a 0.45 μm Whatman
Protran Nitrocellulose Transfer membrane (Whatman
GmbH, Germany) by electroblotting (Bio-Rad CriterionBlotter). The nitrocellulose blots were incubated overnight
(4°C) with specific antibodies directed against: myosin
light chains 1 (MyLC-1) and −3 (MyLC-3) (#F310) (De-
velopmental Studies Hybridoma Bank, Iowa City, IA,
USA), myosin heavy chain fast (MyHC-f ) (#M4276)
(Sigma-Aldrich), p-eIF2Bε (Ser539) (#44-530G) (Invitro-
gen), p-mTOR (Ser2448) (#2971), mTOR (#2983), p-Akt
(Ser473) (#9271), Akt (#9272), p-GSK-3β (Ser9) (#9336),
GSK-3β (#9332), p-p70S6K (Thr389) (#9206), p70S6K
(#2708), p-4E-BP1 (Thr37/46) (#9459), 4E-BP1 (#9452),
p-S6 (Ser235/236) (#2211), p-FoXO1 (Ser256) (#9461),
FoXO1 (#2880), p-FoXO3a (Ser253) (#9466), FoXO3a
(#2497) and GAPDH (#2118) (all from Cell Signaling
Technology), diluted in 1× TBS/0.1% Tween-20. The
blots were probed with a peroxidase conjugated secondary
antibody (#PI-1000) (Vector Laboratories, CA, USA), and
visualized using Supersignal WestPico Chemiluminescent
Substrate (Pierce Biotechnology) according to the man-
ufacturer’s instructions and exposed to Super RX film
(FUJIFILM, Japan). The Western blot films were digita-
lized using a Bio-Rad GS-800 Densitometer and subse-
quent quantification was done using Quantity One
software (version 4.5.0) (both from Bio-Rad).
Statistical analysis
The raw data were entered into SPSS (version 20.0) for
statistical analysis. All values are represented as means
and error bars indicate the standard error of the mean
(SEM). Comparisons of mean values were tested paramet-
rically, using a one-way ANOVA followed by a post hoc
Fischer’s LSD test. The changes in body weight were tested
using a mix-model design ANOVA. Mean value compari-
sons of in vitro data were tested non-parametrically, using
the Mann–Whitney U-test. A two-tailed probability
value (p < 0.05) between groups was considered statisti-
cally significant.
Results
GSK-3 inhibition prevents pulmonary inflammation-
induced skeletal muscle atrophy
Throughout the experimental procedures, neither LPS
nor the concomitant administration of LPS and SB216763
significantly affected the increase in body weight of the
guinea pigs (Figure 1A). However, from week 4 onwards
the increase in body mass of the SB216763-treated
saline-challenged group was significantly lower com-
pared with the vehicle-treated, saline-challenged group
(p < 0.05) (Figure 1A). Repeated LPS administration
consistently appeared to decrease muscle wet weights
(M. plantaris: -2%, M. gastrocnemius: -8%, M. tibialis: -5%,
M. EDL: -7%), although this did not reach statistical sig-
nificance (Figure 1B). Intriguingly, SB216763-treatment
significantly prevented the LPS-induced reduction in these
skeletal muscle weights (except for M. EDL). To verify the
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Figure 1 (See legend on next page.)
Verhees et al. Respiratory Research 2013, 14:117 Page 5 of 15
http://respiratory-research.com/content/14/1/117
(See figure on previous page.)
Figure 1 GSK-3 inhibition prevents skeletal muscle atrophy induced by pulmonary inflammation. (A) Body weight change of the guinea
pigs during the experimental procedures. (B) Effects of repeated LPS exposure and GSK-3 inhibition (SB216763) on skeletal muscle wet weights.
(C) The fiber cross-sectional area (CSA) of muscle fibers in the extensor digitorum longus (EDL) muscle of the guinea pigs was determined from
laminin-stained cross-sections. Representative laminin-stained (white) cross-sections of the same region within the EDL muscle for each experi-
mental group (20X magnification, scale bar = 50 μm). Histogram of quantitative analysis of the mean Type II cross-sectional area (CSA) (n = 7 per
group). (D) Fiber size distribution curves of fiber cross-sectional areas of fibers in the EDL. All data shown represent means ± SEM, n = 9 animals
per group. ***p < 0.001 compared with the vc control group; # p < 0.05, ### p < 0.001 refers to a difference between indicated conditions.
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muscle was determined. The glycolytic EDL muscle pre-
dominantly consisted of Type II fibers (96.4%, data not
shown), and immunohistochemical staining revealed that
chronic LPS administration significantly decreased the
mean Type II fiber CSA compared with vehicle control-
treated muscle (Figure 1C). The decline in Type II fiber
CSA following LPS was further substantiated by examin-
ing the fiber size distribution curves, which revealed a left-
ward shift (smaller fiber size) compared with the fiber
distribution of vehicle-treated control animals (Figure 1D).
Strikingly, pharmacological GSK-3 inhibition abrogated
the reduction of mean Type II fiber CSA in response to
LPS (Figure 1C and Figure 1D). Unexpectedly, GSK-3
enzyme inhibition caused a significant decrease in mean
Type II fiber CSA in EDL muscle of vehicle-treated ani-
mals (Figure 1C). Nevertheless, collectively these data
indicate that muscle atrophy induced by chronic LPS chal-
lenge is prevented by GSK-3 inhibition despite sustained
pulmonary inflammation.
Muscle protein turnover signaling is not affected
following chronic LPS-treatment and GSK-3 inhibition
To address the potential contribution of altered protein
synthesis signaling to the muscle atrophy phenotype, the
protein levels and the phosphorylation state of mTOR
and its downstream effectors p70S6K and 4E-BP1 as well
as Akt, the upstream activator of mTOR were assessed.
The phosphorylated (p)-Akt to Akt ratio in LPS control
muscle was unchanged following a 12 week treatment
regimen with intranasally instilled LPS. Likewise, the p-
Akt levels in muscle exposed to SB216763 alone or in
combination with LPS remained unaltered, comparable
to vehicle/saline-treated controls (Figure 2A). Similarly,
the phosphorylation state and abundance of GSK-3β, a
direct downstream substrate of Akt, was unaffected in
any of the conditions. Chronic pharmacological GSK-3
inhibition by SB216763 in the lung did not result in de-
tectable alterations in the phosphorylation state of the
GSK-3β substrate eIF2Bε (Figure 2A).
Furthermore, the ratio of p-mTOR over total mTOR
was unaffected in any of the conditions. The phosphoryl-
ation state of p70S6K, a downstream substrate of mTOR,
was unaffected by LPS instillation or GSK-3 inhibition
(Figure 2B). In contrast, phosphorylation of S6, a substrateof p70S6K, tended to be reduced upon LPS instillation,
but these findings did not reach statistical significance
(Figure 2B). Finally, repeated LPS administration or GSK-
3 inhibition did not affect p-4E-BP1 or total 4E-BP1 pro-
tein abundance, as another downstream substrate of
mTOR (Figure 2B). Both phosphorylated levels of FoXO1
as well as total FoXO1 protein abundance remained
unaltered following either LPS -or SB216763-treatment
(Figure 2C). In contrast, the p-FoXO3a to FoXO3a ratio
was reduced in response to concomitant LPS and
SB216763-treatment, which is indicative of increased
FoXO3a activity (Figure 2C). Altogether these data imply
that gross alterations in skeletal muscle protein turnover
signaling could not account for the muscle atrophy ob-
served in response to chronic pulmonary inflammation,
nor the prevention thereof by pharmacological GSK-3
inhibition.
GSK-3 inhibition prevents TNF-α-induced impairment of
myogenesis
In addition to alterations in protein turnover, impaired
myogenesis may lie at the basis of sustained muscle wast-
ing [48,49]. Moreover, systemic inflammation resulting
from pulmonary inflammation can trigger muscle atrophy
[26], and inflammatory cytokines have been shown to
contribute to muscle wasting through the inhibition of
myogenic differentiation [43]. To investigate whether
pharmacological GSK-3 inhibition prevents impaired
myogenesis, differentiating C2C12 myoblasts were cul-
tured in the presence or absence of LiCl and/or TNF-α.
LiCl is a direct and indirect inhibitor of GSK-3 and has
been widely used to investigate the role of GSK-3
[50,51]. TNF-α supplementation resulted in diminished
myogenesis of C2C12 myocytes (Figure 3A). Subsequent
quantification of myotube formation, by determining
the myogenic index, clearly demonstrated that TNF-α
reduced myoblast fusion (Figure 3B). Conversely, LiCl
increased myotube formation, and importantly, markedly
attenuated the TNF-α-induced decrease in myotube for-
mation (Figure 3B). TNF-α significantly decreased the
myofibrillar protein abundance, i.e. MyHC-f, MyLC-1
and MyLC-3, whereas LiCl stimulated their expression
(Figure 3C). Notably, LiCl significantly abrogated the re-
duction in contractile protein content in response to
TNF-α (Figure 3C). In addition to reduced expression of
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Figure 2 (See legend on next page.)
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Figure 2 Muscle protein turnover signaling is not affected following chronic LPS-treatment and GSK-3 inhibition. Protein synthesis and
protein degradation-related signaling molecules were determined in whole muscle homogenates of the extensor digitorum longus (EDL) muscles
by Western blot analysis of guinea pigs that were treated intranasally with LPS or SB216763 for 12 weeks. Representative immunoblots depict pro-
tein levels of (A) phospho-Akt (p-Akt), total Akt, phospho-GSK-3β (p-GSK-3β), total GSK-3β, phospho-eukaryotic initiation factor 2Bε (p-eIF2Bε),
GAPDH, (B) phospho-mammalian target of rapamycin (p-mTOR), total mTOR, phospho-p70S6K (p-p70S6K), total p70S6K, phospho-S6 (p-S6),
phospho-4E-BP1 (p-4E-BP1), total 4E-BP1, GAPDH, (C) phospho-FoXO1 (p-FoXO1), total FoXO1, phospho-FoXO3a (p-FoXO3a), total FoXO3a and
GAPDH. The accompanying bar graphs show the densitometric analysis results (means ± SEM, n = 6), represented as a percentage of the vc con-
trol group corrected for GAPDH. All data is shown as a ratio of phospho- to total protein for each target (except p-eIF2Bε, p-S6 and (p-) 4E-BP1).
*p < 0.05 compared with the vc control group. NS: not significant.
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markedly decreased MCK activity. Conversely, enzymatic
GSK-3 inhibition increased basal MCK activity and
prevented the TNF-α-induced decline in MCK activity
(Figure 3D). The differentiation-induced transcriptional
activation of the TnI promoter was diminished in re-
sponse to TNF-α, and increased following GSK-3 inhib-
ition (Figure 3E). In line with the other markers of
myogenesis, LiCl-treatment significantly reversed the
reduction in TnI promoter transactivation in response
to TNF-α.
GSK-3 inhibition blocks glucocorticoid-induced inhibition
of myogenesis
Systemic inflammation increases circulating levels of cor-
tisol; a potent trigger of muscle atrophy [52,53]. Repeated
intranasal LPS instillation in guinea pigs resulted in an
increase in plasma cortisol levels (229%, ± 48.4%), which
was unaffected by SB213763-treatment (172%, ±SEM
51.2%). Previously it was demonstrated that the synthetic
GCs prednisolone as well as Dex strongly impair myogen-
esis [54]. The addition of Dex to the culture medium dur-
ing differentiation resulted in impaired C2C12 myotube
formation (Figure 4A). Similar to the results obtained with
TNF-α, pharmacological GSK-3 significantly prevented
impairment of myoblast fusion in the presence of Dex
(Figure 4B). Furthermore, Dex significantly decreased the
muscle-specific protein expression of MyHC-f, MyLC-1
and MyLC-3, while LiCl supplementation completely pre-
vented this effect (Figure 4C). Moreover, Dex markedly
reduced MCK activity (Figure 4D) and TnI promoter
transactivation (Figure 4E), which was prevented in the
presence of LiCl (Figure 4D and Figure 4E, respectively).
To ascribe the preventive effects of LiCl on impaired myo-
genic differentiation by TNF-alpha or Dex to inhibition
of GSK-3 enzymatic activity, the structurally unrelated
GSK-3 inhibitor CHIR99021 was deployed. Incubation
of differentiating myoblasts with CHIR99021 prevented
or attenuated TNF-alpha-induced blockade of myogenic
fusion or MyLC accumulation (Figure 5A, B), similar as
observed with LiCl. Likewise, pharmacological GSK-3
inhibition using CHIR99021 reversed the Dex-induced
impairment of myogenesis (Figure 5A, C).Discussion
Pulmonary and systemic inflammation in COPD has been
associated with several extra-pulmonary consequences of
the disease [55,56]. A prominent systemic manifestation of
COPD is skeletal muscle atrophy [5,24,25], and the results
presented in this manuscript demonstrate that pharmaco-
logical GSK-3 inhibition is beneficial in preventing muscle
wasting in a model of chronic pulmonary inflammation,
without affecting pulmonary inflammation per se as shown
in the companion paper of this manuscript [57]. Further,
impaired myogenic differentiation of cultured muscle cells,
in response to TNF-α and GCs as putative mediators of
systemic inflammation-induced muscle atrophy, was re-
stored by GSK-3 inhibition, putting forward sustained
myogenesis as a potential basis for the maintenance of
muscle mass despite pulmonary inflammation observed in
this study.
Pulmonary inflammation was induced by repeated in-
tranasal instillation of LPS, an endotoxin that has been
associated with the development of COPD [1,58,59]. Inter-
estingly, the data presented in the companion paper re-
vealed that pulmonary inflammation was not affected by
GSK-3 inhibition [57] suggest that any effects of local
SB216763 instillation on systemic pathology are not
accounted for by alterations in the lung inflammatory re-
sponse. Chronic LPS-treatment resulted in skeletal muscle
atrophy. Similarly, previous work by our group showed
that acute pulmonary inflammation was associated with
muscle atrophy following intra-tracheal LPS instillation
(IT-LPS) [26]. In that study, local inflammation was ac-
companied by a potent systemic inflammatory response,
characterized by elevated circulating levels of inflamma-
tory cytokines, which coincided with increased NF-κB
signaling in skeletal muscle [26]. Systemic inflammation
has been shown to contribute significantly to skeletal
muscle atrophy and pro-inflammatory cytokines have
been suggested to induce and mediate catabolic responses
in muscle via NF-κB signaling [26,60]. In the current study
circulating cytokine levels were not assessed, rendering it
difficult to implicate systemic inflammation as a direct
causal trigger in the onset of muscle atrophy. Neverthe-
less, it is conceivable that, considering the persistent in-
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Figure 3 GSK-3 inhibition by LiCl prevents TNF-α -induced impairment of myogenic differentiation. Differentiating C2C12 myoblasts were
either cultured in the presence or absence of TNF-α (1 ng/ml), LiCl (10 mM) or vc (1.25% BSA) for 72 h after which the cells were assessed for (A)
morphological changes by staining with May-Grünwald Giemsa (40X magnification, scale bar = 500 μm). (B) Myoblast fusion was quantified by de-
termining the nuclear distribution of 1900 or more nuclei for each separate condition. The data is expressed as a percentage of nuclei residing in
cells containing 1, 2, or > 2 nuclei; reflecting mononucleated myoblasts (1 nucleus), dividing or fusing myoblasts (2 nuclei) or myotubes (> 2 nu-
clei), respectively. (C) Next, protein levels of myosin heavy chain fast (MyHC-f), myosin light chains 1 (MyLC-1) and −3 (MyLC-3) and GAPDH were
determined in whole cell lysates by Western blot analysis, (D) or in cell homogenates muscle creatine kinase (MCK) activity was measured spectro-
photometrically, and expressed as specific enzyme activity (units / mg protein). (E) Alternatively, differentiating C2C12 myoblasts containing a
stable genomically integrated troponin I (TnI) luciferase reporter construct were cultured for 72 h in the presence or absence of LiCl (10 mM), or
TNF-α (1 nM) or vc (1.25% BSA). Subsequently, lysates were prepared to measure luciferase activity (RLU / mg total protein). All data shown are
representative of 3 independent experiments (means ± SEM, n = 3). *p < 0.05 compared with vc control; # p < 0.05 refers to a difference between
indicated conditions.
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circulating levels of inflammatory cytokines were reported
in a mouse model of chronic pulmonary inflammation
[24].
During the early onset of inflammation, TNF-α and IL-
1β stimulate the release of GCs, as an endogenous reac-
tion to dampen the inflammatory response, via activation
of the hypothalamic-pituitary-adrenal (HPA) axis [52]. In
this study, pulmonary inflammation was associated with
increases in plasma cortisol levels, providing indirect evi-
dence to support the notion that systemic inflammation
might have occurred in this model. Previously, IT-LPS in-
stillation was reported to increase the plasma concentra-
tion of corticosterone; the endogenous GC in mice [61],
and in other models of inflammation -or GC-associated
muscle atrophy administration of GR-receptor antagonists
prevented or attenuated muscle atrophy [62,63].
Indeed, LPS-induced increases in plasma cortisol were
paralleled by a significant decrease in myofiber CSA,
and only the latter was prevented by GSK-3 inhibition.
Remarkably, basal GSK-3 inhibition likewise resulted in
a decrease in myofiber CSA, which may have been the
consequence of a blunted increase in body weight in re-
sponse to SB216763. Over-inhibition of GSK-3 under
normal circumstances may not be favorable as GSK-3 is
essential in the control of various physiological processes
such as development and cell proliferation [64,65]. As
elevated GSK-3 activity was previously reported in atro-
phying muscle [66], our data may indicate that the use
of GSK-3 inhibitors should be limited to conditions
characterized by aberrant GSK-3 regulation, aimed at res-
toration of physiological GSK-3 activity levels [65,67].
Nevertheless, pharmacological GSK-3 inhibition resulted
in significant sparing of muscle mass and myofiber CSA,
despite sustained pulmonary inflammation and elevated
cortisol levels. This is in line with previously reported
studies highlighting the efficacy of GSK-3 inhibitors in re-
ducing proteolysis in septic muscle [68], and in muscles
from burned rats [69]. Furthermore, GSK-3 inhibition was
demonstrated to decrease general protein degradation
comparably to IGF-I in a model of GC-induced muscleproteolysis [70], and earlier work by our lab delineated a
pivotal role for GSK-3β in the induction of skeletal muscle
atrophy, as loss of GSK-3β expression in muscle resulted
in specific sparing of myofibrillar protein abundance fol-
lowing synthetic GC-treatment [40]. Thus, the inability of
GSK-3 inhibition to reduce pulmonary inflammation im-
plies that the SB216763 inhibitor may have directly inhib-
ited GSK-3 in muscle.
In view of the significance of GSK-3 signaling in the
processes that determine muscle mass [40,65], markers
of protein synthesis and degradation were assessed in
muscle homogenates. As indicated earlier, Akt activation
results in the phosphorylation and cytoplasmic retention of
the FoXO transcription factors, and is responsible for the
subsequent attenuation of protein breakdown. Conversely,
reduced phosphorylation of FoXO, consequent to dimin-
ished Akt activity, may increase proteolysis signaling, and
hence muscle atrophy. Yet, pulmonary inflammation only
appeared to marginally reduce p-FoXO3a protein levels,
while the phosphorylation status of FoXO1 remained un-
affected. It is noteworthy that suppression of GSK-3 activ-
ity did not influence the phosphorylation of FoXO under
any conditions. Of note, these moderate effects of pulmon-
ary inflammation and GSK-3 inhibition on FoXO corre-
sponded to the unaltered phosphorylation state of Akt; its
upstream regulator. Subsequent analysis of other protein
synthesis signaling markers, downstream of Akt, revealed
no demonstrable effects of either LPS -or SB216763-
treatment. In contrast, several in vivo studies established
that LPS-treatment resulted in suppressed protein synthe-
sis in muscle [71,72]. However, these inhibitory effects on
protein synthesis were measured in the acute phase, and a
recent report by Tarabees et al. suggested that endotoxins
only transiently decrease protein synthesis in skeletal
muscle through Akt [73].
A limitation of this study was the fact that besides
FoXO, no additional analyses on muscle protein break-
down signaling were included. Acute loss of muscle mass
typically involves increased proteolysis, in which an im-
portant contribution of the ubiquitin 26S-proteasome sys-
tem (UPS), and largely depends on the rate-limiting E3
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Figure 4 GSK-3 inhibition by LiCl blocks glucocorticoid-induced inhibition of myogenesis. Differentiating C2C12 myoblasts were either
cultured in the presence or absence of dexamethasone (Dex) (10 μM), LiCl (10 mM) or vc (DMSO) for 72 h after which the cells were assessed for
(A) morphological changes by staining with May-Grünwald Giemsa (40× magnification, scale bar = 500 μm). (B) Myoblast fusion was quantified
by determining the nuclear distribution of 1900 or more nuclei for each separate condition. The data is expressed as a percentage of nuclei resid-
ing in cells containing 1, 2, or > 2 nuclei; reflecting mononucleated myoblasts (1 nucleus), dividing or fusing myoblasts (2 nuclei) or myotubes
(> 2 nuclei), respectively. (C) Next, protein levels of MyHC-f, MyLC-1, MyLC-3 and GAPDH were determined in whole cell lysates by Western blot
analysis, (D) and MCK activity was measured spectrophotometrically, expressed as specific enzyme activity (units / mg protein). (E) Alternatively,
differentiating C2C12 myoblasts containing a stable genomically integrated troponin I (TnI) luciferase reporter construct were cultured for 72 h in
the presence or absence of LiCl (10 mM), or Dex (10 μM) or vc (DMSO). Subsequently, lysates were prepared to measure luciferase activity (RLU/
mg total protein). All data shown are representative of 3 independent experiments (means ± SEM, n = 3). *p < 0.05 compared with vc control;
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Figure 5 GSK-3 inhibition using CHIR99021 prevents TNF-α- or glucocorticoid-induced inhibition of myogenesis. Differentiating C2C12
myoblasts were either cultured in the presence or absence of TNF-α (1 ng/ml), dexamethasone (Dex) (10 μM), LiCl (10 mM) or CHIR99021 (2 μM)
or vc (DMSO) for 72 h after which the cells were assessed for (A) morphological changes by staining with May-Grünwald Giemsa (40X magnifica-
tion, scale bar = 500 μm). (B, C) Next, protein levels of MyLC-1 and GAPDH were determined in whole cell lysates by Western blot analysis. All
data shown are representative of 3 independent experiments (means ± SEM, n = 3). *p < 0.05 compared with vc control; # p < 0.05 refers to a
difference between indicated conditions.
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finger 1 (MuRF1) has been postulated [13,74,75]. Due to
limited reagent availability these targets could not be mea-
sured in guinea pig muscle. Although our findings are not
in support of a major role of altered protein turnover in
the development of muscle atrophy in this chronic model,
it is not possible to conclusively rule out its contribution.
First of all, no actual measurements of muscle protein syn-
thesis and degradation were conducted, and the signaling
cues of protein turnover, as assessed here, may not always
correspond with changes in protein synthesis and degrad-
ation [76,77]. Secondly, increased proteolysis has been
reported in response to acute pulmonary inflammation
[26,78]. As elevated muscle breakdown signaling requires
GSK-3β activity [40,68], SB216763-treatment may have
prevented an initial decrease in muscle mass, which sub-
sequently did not recover in the LPS control group despite
the normalization of proteolysis signaling.
Nevertheless, our data suggested that the sustained
muscle atrophy phenotype was not the consequence of
gross alterations in protein turnover. Besides protein turn-
over, myonuclear turnover constitutes another cellular
mechanism determining muscle mass [17]. The sustained
nature of the muscle atrophy phenotype, may have in-
volved impaired regeneration following recovery from at-
rophy, resulting in impaired restoration of muscle mass.
Intriguingly, pharmacological and physiological GSK-3 in-
hibition was recently shown to enhance myoblast fusion
and myotube formation, ascribing an important role to
GSK-3 in the process of myogenesis [41,79]. In the present
study, we made use of the C2C12 cell culture model to in-
vestigate whether GSK-3 inhibition could prevent im-
paired myogenesis in response to TNF-α and the synthetic
GC Dex. Impaired myogenic differentiation in response to
TNF-α [80] has been reported previously, and several lines
of evidence, including our own work, have demonstrated
that, besides their well-described role as inducers of
muscle proteolysis, GCs can also cause muscle atrophy by
inhibiting several aspects of myogenesis [54,81,82].
In agreement with previous findings, TNF-α signifi-
cantly impaired myogenesis in cultured muscle cells,
whereas GSK-3 inhibition improved myogenic differen-
tiation. Importantly, pharmacological GSK-3 inhibition,
using two structurally unrelated inhibitors, completely
prevented reduced myogenesis in response to TNF-α.
Similarly, the Dex-induced impairment of myogenesis
was completely blocked by GSK-3 inhibition using ei-
ther LiCl or CHIR99021. Taken together, interference
with myogenic differentiation, as a direct consequence
of circulating inflammatory mediators or secondary to
increased GC levels, may have resulted in myofiber
atrophy by impaired myogenesis, whereas this process
was sustained by GSK-3 inhibition, resulting in preser-
vation of muscle mass.Collectively, our data demonstrates that topical applica-
tion of the selective GSK-3 inhibitor SB216763 is capable
of preventing skeletal muscle atrophy in a guinea pig
model of pulmonary inflammation. These findings warrant
further exploration of pharmacological inhibition of GSK-3
as a novel therapeutic strategy in the treatment of COPD-
associated skeletal muscle wasting.
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